1209 - Detecting EGFR mutation and its ligands expression in advanced non-small cell lung cancer patients

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Pathology/Molecular Biology
Non-small-cell lung cancer
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Shuai Wang
Authors S. Wang1, X. Han2, J. Li3, X. Hu3, X. Wang3, L. Gui3, L. Zhao3, Y. Sun3, Y. Shi3
  • 1Cancer Hospital-China Academy of Medical Sciences Chao Yang District CAMS and PUMC, 100021 - Beijing/CN
  • 2Clinical Labortary, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
  • 3Medical Oncology, Cancer Hospital-China Academy of Medical Sciences Chao Yang District CAMS and PUMC, 100021 - Beijing/CN



Epidermal growth factor receptor (EGFR) mutations testing for advanced non–small cell lung cancer (NSCLC) patients were found to be predictive of response to EGFR tyrosine kinase inhibitor (TKI). The aim of our study was to explore whether expression levels of ligands of EGFR measured in plasma were predictive of response to EGFR-TKIs.


134 cases of formalin-fixed and paraffin-embedded tumor tissues and paired plasma from advanced NSCLC patients treated by EGFR-TKIs were collected, EGFR mutations were assessed by Scorpions and ARMS using real time PCR. Amphiregulin, transforming growth factor-alpha (TGFa) and TGFb were assessed using enzyme-linked immune-sorbent assay (Elisa). We evaluated the relationship between the EGFR mutation status, concentrations of ligands and response to EGFR-TKIs therapy.


68 (50.7%) of 134 advanced NSCLC patients were detected EGFR somatic mutations. The effect of EGFR-TKIs treatment on progression-free survival (PFS) and overall survival (OS) showed a significant difference by EGFR mutation (p<0.01), but no difference by expression levels of amphiregulin, TGFa and TGFb (p > 0.05, respectively). EGFR mutation rate was found to be higher in women than in men (p < 0.05), and there was no difference between mutation rates with other clinical characteristics. Also, there was no difference between expression levels of ligands with clinical characteristics.


EGFR somatic mutations appear to occur frequently in China, Scorpions and ARMS technology is a sensitive method to detect EGFR mutation and is suitable for screening patients who would like to accept EGFR-TKIs therapy. Ligands of EGFR measured in plasma could not be predictive of response to EGFR-TKIs therapy.


All authors have declared no conflicts of interest.